Methods

Sources. PubMed (E-utilities) for the peer-reviewed literature, ClinicalTrials.gov (API v2) for trial facts, the society and journal sites for guidelines, company releases for regulatory and timing news, Radcliffe Cardiology for video.

Selection. The landmark canon (about 120 papers) was chosen by hand for the site's launch in August 2026: the discovery and genetics papers, the Mendelian randomisation studies, the consensus documents, every phase 1 to 3 trial of an Lp(a)-specific agent, the trial biobank analyses of PCSK9 inhibitors and statins, and the population studies that set thresholds. New publications are added continuously from a PubMed watch on lipoprotein(a) and the agents by name; only papers whose full source is public are included.

Summaries. Written from the abstract and, where available, the paper; numbers are quoted as published (hazard ratios, percent reductions, sample sizes) and never rounded into claims the paper does not make. Each summary links to the original DOI, which remains the source of truth.

Significance (1 to 10). 10 = a paper that changed the field's direction (Clarke and Kamstrup 2009, Thanassoulis 2013, the EAS 2022 consensus, OCEAN(a)-DOSE, the pelacarsen phase 2). 8 to 9 = practice-relevant trials and cohorts. 6 to 7 = useful confirmation, mechanism or sub-analysis. 5 = reviews and orientation.

Units. We quote the units the paper used and add the other where the paper gives both. Conversion between mg/dL and nmol/L is only approximate (see Testing).

Corrections. Every page shows its last-updated date. If a fact is wrong, mail mail@willem.com and it will be fixed with a note.